Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-ASCEND maintenance study of rocatinlimab in moderate-to-severe atopic dermatitis
NL-OMON61450Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rocatinlimab maintenance with Placebo maintenance (2 arms). Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Feb 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON61450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61450.